ArticleCancer immunology research2018
Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice.
Article in Cancer immunology research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 28 citations in OpenAlex.
- Influence of Humoral Response Against GnRH, Generated by Immunization with a Therapeutic Vaccine Candidate on the Evolution of Patients with Castration-Sensitive Prostate Adenocarcinoma.Technology in cancer research & treatmentTrial
- IgM promotes antitumor immunity to a Tn-expressing solid tumor.Journal for immunotherapy of cancer · 2026Article
- Targeting the unfolded protein response for cancer therapy: mitigating tumor adaptation and immune suppression.Biomarker research · 2025Review
- Autoimmunity promotes chronic lymphocytic leukemia progression in an indolent disease model.Scientific reports · 2025Article
- Endoplasmic reticulum stress orchestrates tumor metabolism and immunity: new insights into immunometabolic therapeutics.Frontiers in immunology · 2025Review
- Unraveling the dual roles of tumor-infiltrating antibodies in solid tumors: friend or foe in the tumor microenvironment?Frontiers in immunology · 2025Review
- Endoplasmic Reticulum Stress in Cancer Progression: A Comprehensive Review of Its Role and Mechanisms.International journal of medical sciences · 2025Review
- Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies.Biomarker research · 2023Review
- Decoding endoplasmic reticulum stress signals in cancer cells and antitumor immunity.Trends in cancer · 2022Review
- Loss of AID exacerbates the malignant progression of CLL.Leukemia · 2022Article
- Role of fibrosarcoma-induced CD11bOncogene · 2022Article
- Endoplasmic Reticulum Stress of Oral Squamous Cell Carcinoma Induces Immunosuppression of Neutrophils.Frontiers in oncology · 2022Article
- Self-assembly of X-shaped antibody to combine the activity of IgG and IgA for enhanced tumor killing.Theranostics · 2022Article
- Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway inCancer research · 2021Article
- Targeting the IRE1α/XBP1s pathway suppresses CARM1-expressing ovarian cancer.Nature communications · 2021Article
- Endoplasmic reticulum stress signals in the tumour and its microenvironment.Nature reviews. Cancer · 2021Review
- Potential role of myeloid-derived suppressor cells in transition from reaction to repair phase of bone healing process.International journal of medical sciences · 2021Article
- Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target.Frontiers in immunology · 2021Review
- Development of Tumor-Targeting IRE-1 Inhibitors for B-cell Cancer Therapy.Molecular cancer therapeutics · 2020Article
- Drivers and regulators of humoral innate immune responses to infection and cancer.Molecular immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Chronic lymphocytic leukemia (CLL) cells can secrete immunoglobulin M. However, it is not clear whether secretory IgM (sIgM) plays a role in disease progression. We crossed the Eμ-TCL1 mouse model of CLL, in which the expression of human TCL1 oncogene was driven by the V(H) promoter-Ig(H)-Eμ enhancer, with MD4 mice whose B cells produced B-cell receptor (membrane-bound IgM) and sIgM with specificity for hen egg lysozyme (HEL). CLL cells that developed in these MD4/Eμ-TCL1 mice reactivated a parental Ig gene allele and secreted IgM, and did not recognize HEL. The MD4/Eμ-TCL1 mice had reduced survival, increased myeloid-derived suppressor cells (MDSC), and decreased numbers of T cells. We tested whether sIgM could contribute to the accumulation of MDSCs by crossing μS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.